ライフサイエンスコーパス: radioactive iodine

1 Radioactive iodine vs no radioactive iodine.

2 eceived radiotherapy; and 15 (4.1%) received radioactive iodine.

3 when used either unconjugated or attached to radioactive iodine.

4 O prostate cancer patients were treated with radioactive iodine 125 (125I) prostate implants followed

5 e tumor immediately before implantation of a radioactive iodine 125 plaque as treatment for the tumor

6 tes at 6-9 months between a low administered radioactive iodine ((131)I) dose (1.1 GBq) and the stand

7 The use of radioactive iodine ((131)I) for the treatment of thyroid

8 le thyroid cancer not amenable to surgery or radioactive iodine ((131)I) therapy have few satisfactor

9 ysis of studies reporting the performance of radioactive iodine ((131)I) therapy in differentiated th

10 Radioactive iodine ((131)I) therapy may be used to treat

11 nce in surrounding regions, particularly for radioactive iodine ((131)I)-exposed children.

12 Patients with radioactive iodine ((131)I)-refractory locally advanced

13 ivered by the beta-particle emissions of the radioactive iodine ((131)I).

14 n after exposure to low or moderate doses of radioactive iodine-131 (131I) at a young age is a public

15 role in the treatment of thyroid diseases by radioactive iodine 131I.

16 well-differentiated thyroid cancer receiving radioactive iodine (1373/3397 [40.4%] vs 11,539/20,620 [

17 n of differentiated thyroid cancer requiring radioactive iodine ablation (performance status 0-2, tum

18 tomy and central neck dissection followed by radioactive iodine ablation and thyroid hormone suppress

19 However, recurrence rates following radioactive iodine ablation have previously only been re

20 currence rate among patients who had 1.1 GBq radioactive iodine ablation was not higher than that for

21 or Graves disease include antithyroid drugs, radioactive iodine ablation, and surgery.

22 hyroidism is treated with antithyroid drugs, radioactive iodine ablation, or thyroidectomy.

23 possible lymphadenectomy, and postoperative radioactive iodine administration.

24 ntiated thyroid cancer patients treated with radioactive iodine after total thyroidectomy was assesse

25 Use of radioactive iodine after total thyroidectomy.

26 f developing a single agent that can deliver radioactive iodine and also direct cellular immune funct

27 tatic papillary thyroid cancer refractory to radioactive iodine and positive for the BRAF(V600E) muta

28 ugs, which reduce thyroid hormone synthesis, radioactive iodine and surgery.

29 iate-risk disease, for which use of adjuvant radioactive iodine and surveillance intensity are not cu

30 prophylactic central neck dissection, use of radioactive iodine, and degree of thyrotropin suppressio

31 Antithyroid drugs, radioactive iodine, and surgery are the traditional trea

32 r hyperthyroidism include antithyroid drugs, radioactive iodine, and thyroidectomy, whereas thyroidit

33 During nuclear waste disposal process, radioactive iodine as a fission product can be released.

34 e determination of aqueous concentrations of radioactive iodine as I2, I(-), and IO3(-).

35 In conclusion, persons exposed to radioactive iodines as children and adolescents have an

36 This cohort study found that the risk of radioactive iodine-associated second primary malignant n

37 was an increase in the proportion receiving radioactive iodine between 1990 and 2008; much of the va

38 s an efficient platform for highly effective radioactive iodine capture under industrial operating co

39 g zeolites may offer a more secure route for radioactive iodine capture, with the potential to more e

40 e the strengths of the hybrid by considering radioactive iodine capture.

41 accident in 1986 exposed many individuals to radioactive iodines, chiefly (131)I, the effects of whic

42 ancer in children and adolescents exposed to radioactive iodines, chiefly iodine-131 ((131)I), after

43 ular goiter, before and after treatment with radioactive iodine compared to healthy controls.

44 We aimed to compare recurrence rates between radioactive iodine doses in HiLo.

45 cularly the extent of lymph-node dissection, radioactive iodine dosing, and the role of genetic analy

46 local recurrence and may alter postsurgical radioactive iodine dosing.

47 Childhood radioactive iodine exposure from the Chornobyl accident

48 lignant neoplasm among patients who received radioactive iodine for DTC varies significantly by age g

49 ar cell to take up iodine permits the use of radioactive iodine for follow-up and therapy.

50 of diagnosis, followed by administration of radioactive iodine for remnant ablation.

51 ssociated with greater hospital-level use of radioactive iodine for stage I disease.

52 resection is associated with greater use of radioactive iodine for stage I thyroid cancer.

53 resection is associated with greater use of radioactive iodine for stage I thyroid cancer.

54 certainty persists about the indications for radioactive iodine for thyroid cancer.

55 further evidence in favour of using low-dose radioactive iodine for treatment of patients with low-ri

56 were similar between low-dose and high-dose radioactive iodine groups (3 years, 1.5% vs 2.1%; 5 year

57 localization in 2 patients and placement of radioactive iodine I 125 (125I)-labeled seeds in 10 pati

58 cedure [marking the axillary lymph node with radioactive iodine (I) seeds] is a new minimal invasive

59 They were also more likely to favor radioactive iodine in patients with intrathyroidal unifo

60 the first time, the speciation of stable and radioactive iodine in the groundwater from the Hanford S

61 atment of differentiated thyroid cancer with radioactive iodine is associated with a small increase i

62 mph node metastases, surgery with or without radioactive iodine is curative in most cases.

63 Although radioactive iodine is effective, its appropriate use and

64 Radioactive iodine is of little use.

65 Radioactive iodine is well established as a successful t

66 molecular tag was introduced in the form of radioactive iodine or biotin.

67 andard treatment (surgery followed by either radioactive iodine or observation) is effective.

68 se of antithyroid drugs, whereas for goitre, radioactive iodine or surgery are preferred for toxic no

69 ve treatment is often necessary, either with radioactive iodine or with surgery, ideally performed by

70 Use of radioactive iodine over time and the correlates of its u

71 n) underwent total thyroidectomy followed by radioactive iodine (RAI) ablation.

72 Selumetinib can increase radioactive iodine (RAI) avidity in RAI-refractory tumor

73 s with differentiated thyroid cancer, use of radioactive iodine (RAI) does not improve survival or re

74 rbidity in thyroid cancer patients receiving radioactive iodine (RAI) for remnant ablation or therapy

75 The early history of the use of radioactive iodine (RAI) is complicated and interesting,

76 though surgery is the mainstay of treatment, radioactive iodine (RAI) is routinely used for adjuvant

77 Radioactive iodine (RAI) is safe and effective in most p

78 Postoperative radioactive iodine (RAI) remnant ablation for differenti

79 pean Thyroid Association generally recommend radioactive iodine (RAI) therapy after surgery only for

80 (TL), total thyroidectomy (TT), and TT plus radioactive iodine (RAI) therapy after the 2009 and 2015

81 C who were refractory to further surgical or radioactive iodine (RAI) therapy as reviewed at a multis

82 High-activity radioactive iodine (RAI) therapy for metastatic thyroid

83 Decision-making on adjuvant radioactive iodine (RAI) treatment for early-stage papil

84 The optimal management of radioactive iodine (RAI) treatment in patients with meta

85 fferentiated thyroid cancer (DTC) and use of radioactive iodine (RAI) treatment increased markedly.

86 sease may be treated with antithyroid drugs, radioactive iodine (RAI), or surgery (near-total thyroid

87 initially-treated/recurrent lymph nodes and radioactive iodine (RAI)-refractory distant metastases,

88 idectomy (TT), neck dissection, and adjuvant radioactive iodine (RAI).

89 tant metastases and may become refractory to radioactive iodine (RAI).

90 ed thyroid cancer (WDTC) treated or not with radioactive iodine (RAI).

91 y) were treated with (131)I (radioiodine, or radioactive iodine [RAI]); the median follow-up was 10 y

92 PDTC), anaplastic thyroid cancers (ATC), and radioactive iodine-refractory (RAIR) differentiated thyr

93 Food and Drug Administration for metastatic, radioactive iodine-refractory differentiated thyroid can

94 ed with placebo in patients with progressive radioactive iodine-refractory differentiated thyroid can

95 eatment option for patients with progressive radioactive iodine-refractory differentiated thyroid can

96 (400 mg orally twice daily) in patients with radioactive iodine-refractory locally advanced or metast

97 rospective study, 8 patients with metastatic radioactive iodine-refractory TC received trametinib plu

98 Radioactive iodine-refractory thyroid cancer (TC) has a

99 tent of resection and medical treatment with radioactive iodine remains unknown.

100 d stimulating hormone (rhTSH) for (1)(3)(1)I radioactive iodine remnant ablation in patients with low

101 rasounds (OR, 1.58; 95% CI, 1.17-2.14), >= 1 radioactive iodine scan (OR, 1.73; 95% CI, 1.19-2.50), a

102 confirmed positive axillary lymph node with radioactive iodine seed (MARI) procedure, was performed

103 psy (SLNB), marking axillary lymph node with radioactive iodine seed (MARI), and targeted axillary di

104 Recent studies have confirmed that radioactive iodine therapy after recombinant human TSH (

105 Discussion: Radioactive iodine therapy after thyroidectomy can succe

106 HR, 0.26 [95% CI, 0.12-0.51]) compared with radioactive iodine therapy alone.

107 fter ablation of thyroid remnants (ATR) with radioactive iodine therapy in patients with unstable Gra

108 s may reassure patients about the effects of radioactive iodine therapy on fertility, although men ma

109 Impact of radioactive iodine therapy on subsequent fertility has b

110 -scintigraphy; responders received high-dose radioactive iodine therapy, and nonresponders continued

111 r Graves' disease include antithyroid drugs, radioactive iodine therapy, and surgery, whereas antithy

112 specific scenarios in which medical therapy, radioactive iodine therapy, or surgery should be offered

113 th significant thyroglobulin reduction after radioactive iodine therapy.

114 over 80 y, when Hertz and Roberts first used radioactive iodine to treat thyroid disease.

115 , histology, presence of distant metastasis, radioactive iodine trapping ability, adjuvant treatment,

116 for age-specific surveillance strategies in radioactive iodine-treated DTC survivors.

117 Radioactive iodine treatment after surgery improves over

118 Radioactive iodine treatment for differentiated thyroid

119 Patients who received radioactive iodine treatment for DTC were identified; th

120 including prophylactic CLND and avoidance of radioactive iodine treatment for DTC, when appropriate.

121 ifocality, nodal and distant metastases, and radioactive iodine treatment.

122 bulinemia and may modify the indications for radioactive iodine treatment.

123 are antithyroid drugs, thyroid surgery, and radioactive iodine treatment.

124 lithium, and immune checkpoint inhibitors), radioactive-iodine treatment, and thyroid surgery, are f

125 patients had low thyroid hormone levels and radioactive iodine uptake in the thyroid gland associate

126 d that there was a statistical difference in radioactive iodine use between American Joint Committee

127 Wide variation in radioactive iodine use existed, and only 21.1% of this v

128 ETTING, AND PATIENTS: Time trend analysis of radioactive iodine use in a cohort of 189,219 patients w

129 s of patient and hospital characteristics on radioactive iodine use in the cohort treated from 2004 t

130 ristics, hospital volume was associated with radioactive iodine use.

131 Radioactive iodine vs no radioactive iodine.

132 In the 15- to 44-year age group, radioactive iodine was associated with an increased risk

133 back to the middle of the last century, when radioactive iodine was first used to treat thyroid disea

134 dy of Graves hyperthyroidism, treatment with radioactive iodine was more likely than methimazole ther

135 Radioactive iodine was not linked to total cancer deaths

136 itive papillary thyroid cancer refractory to radioactive iodine who had never been treated with a mul

137 for thyroid cancer that does not respond to radioactive iodine, with response rates 12% to 65%.